Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02250157
Other study ID # ORTE-01-14-US
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 5, 2014
Est. completion date March 4, 2020

Study information

Verified date February 2022
Source Athenex, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study a nonrandomized, open-label, uncontrolled, single group assignment, safety and activity study in subjects with histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.


Description:

This study consists of Part 1 and Part 2. Part 1 of this study is a "3+3" design to define the MTD of Oratecan in up to 60 evaluable subjects. It will be conducted in 2 parts; 1A will test the oral liquid formulation and 1B will test the oral tablet formulation of irinotecan. Part 2 will enroll an additional 10 subjects at the Part 1 MTD to further characterize the safety, tolerability, pharmacokinetics, and activity of Oratecan at that dose. Irinotecan (CPT-11) is a potent anticancer drug under the class of camptothecins that is marketed under the trade name Camptosar. Irinotecan is a prodrug that is activated via carboxylesterase in liver and intestines to its active form, SN38 which is approximately 1000 times more cytotoxic than irinotecan itself. The investigational product (IP) Oratecan is comprised of the approved drug irinotecan with HM30181 methanesulfonate monohydrate (HM30181), a novel p-glycoprotein (P-gp) pump inhibitor. Oratecan is intended for the treatment of irinotecan-responsive cancers. The antitumor activity of Oratecan is due to the action of irinotecan. Combining HM30181 with irinotecan allows intestinal absorption and systemic exposure of irinotecan and its active metabolite, SN38, at therapeutic levels after oral administration.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date March 4, 2020
Est. primary completion date March 4, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Signed written informed consent. - = 18 years of age. - Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. - Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. - Adequate bone marrow reserve as demonstrated by : - Absolute Neutrophil Count (ANC) = 1.5 x 10?/L. - Platelet count = 100 x 10?/L. - Hemoglobin = 9 g/L. - Adequate liver function as demonstrated by: - Total bilirubin of = 1.5 mg/dL or = 2.0 mg/dL for subjects with liver metastasis. - Alanine aminotransferase = 3 x ULN or = 5 x ULN if liver metastasis is present. - Alkaline phosphatase = 3 x ULN or = 5 x ULN if bone metastasis is present - Adequate renal function as demonstrated by serum creatinine = 1.5 x ULN or 24-hour urine creatinine clearance calculation = 60 mL/min. - Eastern Cooperative Oncology Group performance status of 0 to 1. - Life expectancy of at least 3 months. - Woman must be postmenopausal (> 12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of IP. - Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of IP. Exclusion Criteria: - Subjects who are homozygous for the UGT1A1*28 allele - Have not recovered to = Grade 1 toxicity from previous anticancer treatments or previous IPs. - Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer. - Are currently receiving other medications intended for the treatment of their malignancy. - Women who are pregnant or breast feeding. - Taking a medication known to be clinically significant P-gp inhibitors or inducers within 14 days of treatment with Oratecan. - Chronically taking an oral medication known to be a P-gp substrate within 7 days of starting treatment with Oratecan. - Taking a medication known to be a clinically significant cytochrome (CYP) 3A4 strong inhibitor (eg, ketoconazole within 14 days) or strong inducers (eg, rifampin and St. John's Wort within 14 days) of starting treatment with Oratecan. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteracti onsLabeling/ucm080499.htm - Require therapeutic use of anticoagulation medications - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements. - Major surgery to the upper gastrointestinal (GI) tract, or have a history of GI disease or other medical condition that, in the opinion of the investigator may interfere with oral drug absorption. - Allergy or sensitivity to irinotecan or cranberry-grape juice, or any of the irinotecan tablet excipients. .

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oratecan


Locations

Country Name City State
United States University of Colorado Cancer Center Aurora Colorado
United States Roswell Park Cancer Institute Buffalo New York

Sponsors (1)

Lead Sponsor Collaborator
Athenex, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with dose limiting toxicities 2 years
Secondary Number of patients with adverse events 2 years
Secondary Area under the plasma concentration versus time curve Determine the amount of Oratecan in participants blood (pharmacokinetics) 2 years
Secondary Tumor measurements per RECIST 1:1 Assess preliminary anti-tumor activity 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Recruiting NCT04930432 - Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors Phase 1/Phase 2